News

Myeloma UK is helping to Make Blood Cancer Visible this September

Myeloma UK is helping to Make Blood Cancer Visible in September. The campaign, in partnership with Janssen Oncology and eight patient organisations, marks Blood Cancer Awareness Month. It will feature a public art installation, which will help visitors to understand the experiences of people affected by blood cancer.   The installation is made up of…

Details

Prophylactic antibiotic combination reduces incidence of infection following ASCT

Results from a retrospective study have shown that prophylactic treatment with doxycycline and ciprofloxacin reduces the incidence of infection in myeloma patients following an autologous stem cell transplant (ASCT), when compared to treatment with ciprofloxacin alone. Published in Supportive Cancer Care, the results show that 53% of patients receiving ciprofloxacin alone developed neutropenic fever compared…

Details

Ixazomib combination demonstrates efficacy in relapsed and refractory myeloma patients

Results from a Phase II study, recently published in Leukaemia, show that the oral combination of ixazomib (Ninlaro®), pomalidomide (Imnovid®) and dexamethasone is effective in relapsed and refractory myeloma patients. All patients in this study were refractory to lenalidomide (Revlimid®). 48% of patients who received the recommended dose of ixazomib (4mg) achieved a partial response or…

Details

Pomalidomide combination shows efficacy in relapsed and refractory myeloma patients with renal impairment

Published in the Journal of Clinical Oncology, results from the Phase II trial, MM-013 show that pomalidomide (Imnovid®) in combination with low-dose dexamethasone is effective in relapsed and refractory patients with renal impairment. There were 3 cohorts in this trial; patients with moderate renal impairment (A), severe renal impairment (B) and severe impairment requiring haemodialysis…

Details

EMA recommends expanded denosumab indication for myeloma

Amgen has announced that the European Medicine’s Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation to expand the existing licence for denosumab (Xgeva®) to treat skeletal-related events in myeloma patients. This decision is based on the results from a Phase III trial which compared denosumab to zoledronic acid…

Details